Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AbbVie projects double-digit annual earnings growth through 2020

AbbVie Inc (ABBV.N) reported higher quarterly sales and net income on Friday and forecast double-digit growth of earnings per share through 2020, putting the drugmaker in line to beat Wall Street’s current expectations. AbbVie, which was spun out of Abbott Laboratories in 2013, expects revenue of $37 billion in 2020, which is $5 billion more […]

Read More »

Sanofi Walks Away from a $613 Million Multiple Sclerosis Pact with Glenmark Pharma

PARIS – After experimental multiple sclerosis drug vatelizumab failed to meet its primary endpoints in a mid-stage trial, Sanofi AG (SNY) said it has dropped plans to develop the drug with India-based Glenmark Pharmaceuticals.   During a second-quarter results analysis with media members, Glenmark revealed that Sanofi was terminating the development agreement for vatelizumab, also […]

Read More »

FDA approves new Novartis dual combination bronchodilator Utibron Neohaler for patients with chronic obstructive pulmonary disease

– Utibron Neohaler (indacaterol/glycopyrrolate) demonstrated superior and sustained improvements in lung function compared to either of its single bronchodilator components as well as placebo, and improved lung function compared to placebo at 5 minutes after the first dose and throughout the dosing interval.1 It does not replace the use of a rescue inhaler – Utibron […]

Read More »

Rumors Confirmed, Pfizer and Allergan In Talks to Merge

After months of speculation on who Pfizer Inc. (PFE) will attempt to buy are now officially over — sort of. It has been confirmed that Pfizer Inc. and Allergan Plc (AGN), according to the Wall Street Journal, are discussing a potential merger. The two companies have declined to comment.   Analysts have been speculating on […]

Read More »

FDA expands use of Bristol-Myers’ cancer drug Yervoy

The U.S. Food and Drug Administration expanded the use of Bristol-Myers Squibb Co’s skin cancer drug, Yervoy, as an additional therapy for patients with late-stage melanoma. This approval extends Yervoy’s use to patients with stage III melanoma, who have a high risk of recurrence after surgery, the agency said on Wednesday. Due to the potential […]

Read More »

Gilead hepatitis C drug sales trend flattens, shares dip

Gilead Sciences Inc on Tuesday said its quarterly profit rose 70 percent, but sales growth for its hepatitis C drugs flattened as health insurers limited access to the expensive treatments. Shares of the biotechnology company fell slightly. Gilead’s quarterly product sales rose 37 percent to $8.2 billion. Sales of hepatitis C drugs Sovaldi and Harvoni […]

Read More »

Arena Pharmaceuticals Announces New Strategic Focus and Cost Reduction Plan

– Strategic priorities include clinical-stage pipeline and core research function –   SAN DIEGO, Oct. 27, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities. Arena intends to focus on its key strengths by concentrating […]

Read More »

Shire to resubmit dry-eye disease drug to FDA with new study data

London-listed pharma firm Shire said its dry-eye disease drug lifitegrast significantly improved patient symptoms in a new study, supporting a re-submission of the potentially block-busting medicine to U.S. regulators early next year. Shares in Shire jumped more than 6 percent after it announced the positive results of the study on Tuesday. They were trading up […]

Read More »

Novartis AG to Cough Up $390 Million to Settle U.S. Kickback Case

Novartis AG agreed to pay $390 million to resolve a lawsuit claiming the company paid kickbacks to increase sales of several prescription drugs. The agreement is preliminary. The payment covers all claims related to the medicines Myfortic, Exjade, Tasigna, Gleevec and TOBI, the company said. The U.S. had sought as much as $3.3 billion from […]

Read More »

FDA sees no heart risks from Novartis’ Parkinson’s drug

U.S. health regulators said on Monday that there was no evidence of increased cardiovascular risks related to Novartis AG’s treatment, Stalevo, for Parkinson’s disease. Recommendations for using the drug, which won U.S. approval in 2003, will remain the same on the labels, the U.S. Food and Drug Administration said, after examining data from a required […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom